NCT01563731View on ClinicalTrials.gov

Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2020

Study Completion Date

March 31, 2021

Conditions
StrokeTransient Ischemic AttackHypertension
Interventions
DRUG

all approved antihypertensive drugs; all approved statins

All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.

Trial Locations (1)

197341

Almazov Federal Heart, Blood and Endocrinology Centre, Saint Petersburg

All Listed Sponsors
collaborator

European Society of Hypertension

OTHER

collaborator

Chinese Hypertension League

UNKNOWN

lead

Istituto Auxologico Italiano

OTHER

NCT01563731 - Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives | Biotech Hunter | Biotech Hunter